Q2 25 EPS
$2.77
BEAT +3.43%
Est. $2.68
Q2 25 Revenue
$23.74B
BEAT +3.88%
Est. $22.86B
vs S&P Since Q2 25
+24.9%
BEATING MARKET
JNJ +39.7% vs S&P +14.7%
Market Reaction
Did JNJ Beat Earnings? Q2 2025 Results
Johnson & Johnson capped a strong second quarter with results that cleared Wall Street's bar on both the top and bottom lines, as the healthcare giant's diversified portfolio proved resilient even in the face of meaningful headwinds. Adjusted diluted… Read more Johnson & Johnson capped a strong second quarter with results that cleared Wall Street's bar on both the top and bottom lines, as the healthcare giant's diversified portfolio proved resilient even in the face of meaningful headwinds. Adjusted diluted EPS came in at $2.77, beating the $2.68 consensus by 3.43%, while revenue climbed 5.8% year over year to $23.74 billion, topping expectations of $22.86 billion by 3.88%. The driving force behind the beat was a powerful oncology surge within its Innovative Medicine segment, led by DARZALEX at $3.54 billion and ERLEADA growing 23.4%, which helped absorb a 42.7% decline in STELARA as biosimilar competition continued to erode that franchise. MedTech contributed meaningfully as well, with cardiovascular growing 23.5% on the strength of electrophysiology and structural heart products. Management backed the momentum by raising full-year 2025 guidance, lifting the adjusted EPS midpoint by $0.25 to $10.85 and increasing expected reported sales growth to approximately 5.4%.
Key Takeaways
- • DARZALEX worldwide sales growth of 23.0% driven by oncology demand
- • CARVYKTI rapid ramp contributing $439M in Q2 worldwide sales
- • TREMFYA growth of 31.0% driven by immunology expansion including ulcerative colitis
- • SPRAVATO growth of 53.3% in neuroscience
- • ERLEADA growth of 23.4% in prostate cancer
- • MedTech Cardiovascular growth of 23.5% driven by electrophysiology, Abiomed, and Shockwave
- • Intra-Cellular Therapies acquisition adding CAPLYTA with $211M in first quarter contribution
- • Favorable foreign exchange contributing 1.2 percentage points to total reported growth
JNJ YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
JNJ Revenue by Segment
With YoY comparisons, source: SEC Filings
JNJ Revenue by Geography
With YoY comparisons, source: SEC Filings
“Today's strong results reflect the depth and strength of Johnson & Johnson's uniquely diversified business operating across both MedTech and Innovative Medicine.”
— Joaquin Duato, Q2 2025 Earnings Press Release
JNJ Earnings Trends
JNJ vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
JNJ EPS Trend
Earnings per share: estimate vs actual
JNJ Revenue Trend
Quarterly revenue: estimate vs actual
JNJ Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $2.70 | — | $24.06B | +1.89% |
| Q4 25 BEAT FY | $2.46 | $2.46 | +0.00% | $24.56B | — |
| FY Full Year | $10.80 | $10.79 | -0.13% | $94.19B | +0.46% |
| Q3 25 BEAT | $2.76 | $2.80 | +1.49% | $23.99B | +1.00% |
| Q2 25 BEAT | $2.68 | $2.77 | +3.43% | $23.74B | +3.88% |
| Q1 25 BEAT | $2.58 | $2.77 | +7.34% | $21.89B | +1.48% |